Elicio Therapeutics received FDA feedback supporting ELI-002's Phase 3 study design; Phase 2 analysis results expected in H1 2025. Elicio Therapeutics announced positive feedback from the FDA ...
Detroit Arsenal, Mich. (Dec. 9, 2020) - Today, the U.S. Army conducted a virtual Industry Day for the Optionally Manned Fighting Vehicle (OMFV) program to provide an overview of the program’s ...
Operational data such as torque, vibration, and temperature are vital for refining machine design and predicting failure modes. Feedback from real-world machines reduces over-engineering, cuts costs, ...
LUND, SE / ACCESS Newswire / March 5, 2025 / Cantargia (STO:CANTA) Promising multiple dose PK data continue to support 4-weekly dosing FDA advice received supporting phase 2 design in HS Strong Key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results